Abstract Number: 421 • 2013 ACR/ARHP Annual Meeting
Enhanced Cardiovascular Risk Factor Screening In Rheumatoid Arthritis: Does This Have a Sustained Impact?
Background/Purpose: Rheumatoid Arthritis (RA) patients face a burden of cardiovascular disease (CVD) twice that of the general population. RA patients have reduced physical fitness, a…Abstract Number: 422 • 2013 ACR/ARHP Annual Meeting
Disease Activity In Rheumatoid Arthritis Is Associated With Abnormal Left Ventricular Geometry
Background/Purpose :Disease activity is related to risk of cardiovascular (CV) disease in rheumatoid arthritis (RA) patients1,2. Left ventricular (LV) geometry strongly predicts CV mortality and…Abstract Number: 423 • 2013 ACR/ARHP Annual Meeting
Serological Biomarkers For The Development Of Rheumatoid Arthritis Related Interstitial Lung Disease
Background/Purpose: Interstitial Lung Disease (ILD) is the commonest manifestation of lung disease in Rheumatoid Arthritis (RA) and the only complication reported to be increasing in…Abstract Number: 424 • 2013 ACR/ARHP Annual Meeting
2-Year Results From The Ample (Abatacept versus Adalimumab Comparison in Biologic-Naïve RA Patients with Background Methotrexate) Trial: Changes In Patient-Reported Outcomes In Response To Subcutaneous Abatacept Or Adalimumab In Rheumatoid Arthritis
Background/Purpose: RA is a debilitating disease that can impact health-related quality of life (HRQoL) through impairment of activity, loss of independence and reduced work productivity.…Abstract Number: 425 • 2013 ACR/ARHP Annual Meeting
Efficacy, Pharmacokinetics, and Safety of Different Doses of Methotrexate in Combination With Adalimumab: Results From the Concerto Trial
Background/Purpose: Anti-TNF plus methotrexate (MTX) is more effective than either as monotherapy. Thus far, no controlled data are available on the benefit:risk of different doses…Abstract Number: 426 • 2013 ACR/ARHP Annual Meeting
Characteristics of Protocol-Specified Responders/Non-Responders Treated With Etanercept Plus Methotrexate in Period 1 of the Prize Study
Background/Purpose: Although frequently effective, treatment with synthetic or biologic disease-modifying antirheumatic drugs (DMARDs) does not adequately control disease activity in all patients. Prompt identification of…Abstract Number: 427 • 2013 ACR/ARHP Annual Meeting
US Veterans With Rheumatoid Arthritis Who Switch Among Tumor Necrosis Factor Blocking Agents Have No Additional Clinical Benefit With The Change In Therapy and Incur Higher Costs
Background/Purpose: While tumor necrosis factor (TNF) blockers can be effective in treating rheumatoid arthritis (RA), the benefit of switching among TNF blockers is not clear.…Abstract Number: 428 • 2013 ACR/ARHP Annual Meeting
Correlation Between Objective and Patient Self-Reported Clinical Improvement After Multiple Courses of Rituximab in Rheumatoid Arthritis Patients With Inadequate Response to Tumour Necrosis Factor Inhibitors: Data From Repeat Study
Background/Purpose: Rituximab (RTX) has been evaluated in many clinical trials and objective assessment of rheumatoid arthritis (RA) activity must comply with Treat to Target principles.…Abstract Number: 429 • 2013 ACR/ARHP Annual Meeting
Sustained Clinical Efficacy After Multiple Courses of Rituximab in Rheumatoid Arthritis Patients With Inadequate Response to Tumour Necrosis Factor Inhibitors: 2-Year Data From the Repeat (Repeated Courses in Routine Clinical Practice) Study
Background/Purpose: In the last decade, biologic therapy changed dramatically treatment options for rheumatoid arthritis (RA). However, a significant number of patients failed to maintain the…Abstract Number: 430 • 2013 ACR/ARHP Annual Meeting
Comparing abatacept to Adalimumab, Etanercept and Infliximab As First Or Second Line Agents in Patients With Rheumatoid arthritis: Experience From the rhumadata® Clinical Database and Registry
Background/Purpose: The order of use of biologic agents is still a question for debate. Phase III trial data in MTX-IR patients show comparable efficacy results…Abstract Number: 431 • 2013 ACR/ARHP Annual Meeting
Prediction Of Week 52 Treatment Response Based On A Week 12 Assessment In Rheumatoid Arthritis Patients Receiving Certolizumab Pegol: Comparison Of A Patient-Reported Instrument Versus Physician-Based Disease Activity Assessment
Background/Purpose: Guidelines support early intervention in rheumatoid arthritis (RA).1,2 The aim was to prospectively test whether outcome assessment at 12 weeks (wks) using a patient-reported…Abstract Number: 432 • 2013 ACR/ARHP Annual Meeting
Use Of Rituximab As Second Line Biologic Agent Compared With Adalimumab, Etanercept and Infliximab In Patients With Rheumatoid Arthritis. a Report From The Rhumadata® Clinical Database and Registry
Background/Purpose: The order of use of biologic agents after failing a TNF inhibitor is still a question for debate. Phase III trial data in TNF-IR…Abstract Number: 433 • 2013 ACR/ARHP Annual Meeting
Retrospective Analysis Of Certolizumab Pegol Use During Pregnancy: Update Of Impact On Birth Outcomes
Background/Purpose: Certolizumab pegol (CZP) is a PEGylated Fc-free anti-TNF approved in 45 countries for the treatment of rheumatoid arthritis (RA) and/or Crohn's disease (CD). An…Abstract Number: 434 • 2013 ACR/ARHP Annual Meeting
Results Of 64 Weeks Of Treatment With An Anti-IL-17 Antibody, Ixekizumab, In Patients With Rheumatoid Arthritis In a Phase 2 Study
Background/Purpose: Ixekizumab, a monoclonal antibody that neutralizes IL-17A with high affinity and specificity, has been evaluated in patients (pts) with moderate to severe rheumatoid arthritis…Abstract Number: 435 • 2013 ACR/ARHP Annual Meeting
Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized, Placebo-Controlled Trial Of Golimumab In Methotrexate-naïve Patients With Rheumatoid Arthritis
Background/Purpose: Final 5yr safety and efficacy results of subcutaneous golimumab (GLM)+/-MTX evaluated in a phase 3 trial (GO-BEFORE) of MTX-naïve pts with rheumatoid arthritis (RA)…
ACR Meeting Abstracts